Evidence map›Paper›PMID 42701949›Full record

ReviewAging cell2026

Twisting the End Game: How Telomere Chromatin Modifications Shape Telomere Maintenance.

Jie Wang, Yuehui Su, Chao Chen, Yueying Li, Jiajia Han, Liping Du, Liyun Zheng, Ya-Long Dang, Ying Peng

Abstract readReview
In one paragraph

Review in Aging cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jie WangDepartment of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.ORCID https://orcid.org/0000-0002-6901-334X
Yuehui SuDepartment of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Chao ChenDepartment of Critical Care Medicine, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, Henan, China.
Yueying LiHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Jiajia HanDepartment of Infectious Diseases, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, Henan, China.ORCID https://orcid.org/0000-0003-1311-8166
Liping DuHenan International Joint Research Laboratory for Ocular Immunology and Retinal Injury Repair, Department of Ophthalmology, Henan Province Eye Hospital, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.ORCID https://orcid.org/0000-0001-5168-1756
Liyun ZhengHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Ya-Long DangSanmenxia Central Hospital, Henan University of Science and Technology, Sanmenxia, Henan, China.ORCID https://orcid.org/0000-0003-2194-6375
Ying PengHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.

Funding

Henan Institute of Pharmaceutic and Medical sciences Innovation team grant 2026BP0102Henan provincial key research and development 261111312100Henan Provincial Natural Science Foundation 262300420609Key Scientific and Technological Project of Henan Province 262102310328
6 · The paper itself

Abstract

Cell division inevitably shortens telomeric DNA owing to the end-replication problem. Eukaryotic chromosomes possess specialized telomere structures to maintain genomic stability. In most proliferative cells, telomerase adds telomeric repeats during S-phase. In differentiated cells where telomerase is silenced, telomeres shorten progressively, thereby compromising genomic integrity. Consequently, cancer cells universally activate alternative telomere maintenance mechanisms during malignant transformation: ~80% reactivate telomerase, while a portion of the rest rely on BIR (break-induced replication)-mediated homologous recombination-based ALT (alternative lengthening of telomeres). Although these mechanisms are stable once established, the initial determinants influencing a cancer cell's choice remain poorly understood. This review discusses recent molecular insights into how telomeric chromatin properties profoundly impact this choice. After briefly introducing telomere chromatin characteristics and key players in its maintenance and dynamics, we discuss the mechanisms by which cancer cells acquire distinct telomere replication capabilities. In particular, we present an in-depth analysis linking telomere heterochromatin status to ALT. Furthermore, based on recent advances, we propose a coupled feedforward loop model explaining how the ALT state becomes "locked in" once initiated. Finally, we offer novel perspectives on rational, telomere-centric therapeutic interventions for ALT-positive cancers, focusing on strategies designed to disrupt such feedforward loops by manipulating telomeric chromatin structure.

Indexed as

ChromatinTelomereTelomere HomeostasisAnimalsDNA ReplicationHumansNeoplasmsTelomeraseChromatinTelomerase

Identifiers

PMID42701949
PMCPMC13546678

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.